Caris Life Sciences, Inc.
CAI
Rank in Stocks
#2191
Caris Life Sciences, Inc. operates as a leading "TechBio" firm, harnessing... Caris Life Sciences, Inc. operates as a leading "TechBio" firm, harnessing artificial intelligence to deliver comprehensive molecular profiling services to clients both in the United States and internationally. The company is dedicated to transforming medical care by innovating and bringing to market advanced solutions that leverage molecular data and sophisticated machine learning algorithms. Its extensive suite of molecular diagnostic offerings includes MI Profile, a specialized solution analyzing tissue samples, and Caris Assure, a blood-based test designed for cancer treatment applications. Furthermore, Caris provides research and development support to biopharmaceutical customers, encompassing laboratory delivery, strategic data insights, and dedicated research initiatives. Established in 2008, the company maintains its corporate headquarters in Irving, Texas.
Share Price
$32.28
Last synced: 2026-10-21
Market Cap
$9.12B
Change (1 day)
3.76%
Change (1 year)
7.46%
Country
US
Trade Caris Life Sciences, Inc. (CAI)
Category
Healthcare
Revenue for Caris Life Sciences, Inc. (CAI)
Revenue in Oct 2026 TTM: 0
According to Caris Life Sciences, Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Caris Life Sciences, Inc. from 2026 to 2026
Revenue at the end of each year
| Year | Revenue | Change |
|---|---|---|
| Not enough data for the provided dates. | ||
Revenue for similar companies or competitors
| Company | Revenue | Revenue Difference | Country |
|---|---|---|---|
| $12.62B | - |
US
|
|
| $2.23B | - |
US
|
|
| $15.74B | - |
AU
|
|
| $6.02B | - |
NL
|
|
| - | - |
CH
|
